Navigation Links
Nektar to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets
Date:5/2/2013

, which has completed Phase 3 development as a once- daily, oral tablet for the treatment of opioid-induced constipation.  This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid.  NKTR-181, a novel mu-opioid analgesic candidate for chronic pain conditions, is in Phase 2 development in osteoarthritis patients with chronic knee pain.  NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development.  In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer and is also in Phase 2 studies for the treatment of ovarian and colorectal cancers. In anti-infectives, Amikacin Inhale is in Phase 3 studies conducted by Bayer Healthcare to treat patients with Gram-negative pneumonia.

Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.  Additional development-stage products that leverage Nektar's proprietary technology platform include Baxter's BAX 855, a long-acting PEGylated rFVIII program, which is in Phase 3 clinical development.

Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.  Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
9. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Ind. , Sept. 16, 2014   Evana ... of custom, automated assembly and test systems, recently received ... a leading medical device manufacturer. The Evana solution will ... quality and ergonomics, as well as reduce labor. ... automatically fed to Evana,s robotic assembly cell. The robot ...
(Date:9/16/2014)... 16, 2014   Vestagen Technical Textiles, Inc. ... at hospitals. The myComfort™ line of patient apparel is ... that is fluid repellant, breathable and in studies done ... of bacteria on the fabric i . ... the chain of transmission. We want myComfort to be ...
(Date:9/16/2014)... OKLAHOMA CITY , Sept. 16, 2014 ... biopharmaceutical company developing novel orally active drugs ... existing antibiotics, announced today a $1.4 million ... investing arm of life sciences accelerator Accele ... from i2E, Inc., a nationally recognized private ...
Breaking Medicine Technology:Evana Automation to Supply Robotic Assembly Cell to Leading Medical Device Manufacturer 2Evana Automation to Supply Robotic Assembly Cell to Leading Medical Device Manufacturer 3New Vestagen Patient Garments Aim to Minimize Pathogen Transmission Inside Hospitals 2Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 2Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 3Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 4
... Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), a ... company will actively participate at the Save A Leg, ... in Orlando tomorrow, October 8. , In addition to exhibiting its ... a workshop entitled " The ...
... ACCESS PHARMACEUTICALS, INC . (OTC ... agreement with iMedicor (OTC Bulletin Board: VMCI) for the North ... rinse for the management of oral mucositis and stomatitis caused ... System application, initial introduction of MuGard to the 216,000 selected ...
Cached Medicine Technology:Wound Management to Participate at Save A Leg, Save a Life Foundation National Conference 2Wound Management to Participate at Save A Leg, Save a Life Foundation National Conference 3Access Pharmaceuticals Signs eMarketing Agreement With iMedicor For MuGard(TM) 2Access Pharmaceuticals Signs eMarketing Agreement With iMedicor For MuGard(TM) 3Access Pharmaceuticals Signs eMarketing Agreement With iMedicor For MuGard(TM) 4
(Date:9/16/2014)... Eagan, MN (PRWEB) September 16, 2014 Cliff ... to their team. Kristaleen is the newest dental hygienist to ... Care looks forward to working with her and knows she ... to her patients. , Kristaleen grew up in River Falls, ... Dakota County Technical College in 2003 and practiced dental assisting ...
(Date:9/16/2014)... CO (PRWEB) September 16, 2014 Aspen ... that it has been recognized for its high morale ... Consulting magazine “The Best Small Firms to Work For ... survey annually, with more than 10,000 consultants participating across ... Extensive employee satisfaction surveys were conducted, and firms were ...
(Date:9/16/2014)... therapy as part of breast conservation is the ... positive (HR+) invasive breast cancer. A new study ... shows that combination may not be necessary for ... The results, which Fox Chase researchers presented at ... Meeting on Sunday, September 14, suggest that low-risk ...
(Date:9/16/2014)... York, NY (PRWEB) September 16, 2014 ... children around the world will be honored in New ... Award ( http://www.worldofchildren.org ), the only global recognition and ... , Hailed by the media as the “Nobel ... individuals have each created life-changing programs that benefit children ...
(Date:9/16/2014)... 16, 2014 As part of its ... American Citizens (LULAC) will host the second annual health ... will feature free health screenings for osteoporosis, HIV, and ... glucose and cholesterol levels as well as bone marrow ... children under 6 years old , The event will ...
Breaking Medicine News(10 mins):Health News:Cliff Lake Dental Care Announces Newest Team Member 2Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 2Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 3Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 3Health News:World of Children® Award Announces 2014 Honorees 2Health News:World of Children® Award Announces 2014 Honorees 3Health News:World of Children® Award Announces 2014 Honorees 4Health News:World of Children® Award Announces 2014 Honorees 5Health News:World of Children® Award Announces 2014 Honorees 6Health News:World of Children® Award Announces 2014 Honorees 7Health News:World of Children® Award Announces 2014 Honorees 8Health News:LULAC Hosts Second Annual Latinos Living Healthy Feria de Salud in Los Angeles 2
... EXTON, Pa., Feb. 13 Kensey Nash Corporation (Nasdaq: ... the Canaccord Adams Musculoskeletal Conference at the University ... 24, 2009.Douglas G. Evans, Kensey Nash,s Chief Operating Officer, ... p.m. (ET). The presentation materials will be available ...
... researcher explains , , FRIDAY, Feb. 13 (HealthDay News) -- ... "number sense," but it,s the use of language to ... much higher levels, says a Duke University expert. , ... at Duke, studies how human adults and infants, lemurs ...
... ATSI ), manufacturer and marketer of state-of-the-art cardiac ... financial results,for the fourth quarter ended December 31, 2008, ... The Company will host a conference call and,webcast on ... (2:00 p.m.,Pacific Time) to discuss its fourth quarter and ...
... following is from Betsy McCaughey, Ph.D., the author of the ... Plan."If Keith Olbermann of MSNBC could defend the ... he wouldn,t be resorting to personal attacks on me. ... (2-12-2009). That,s not true.I am not paid by the ...
... Facilities, especially teaching hospitals, have to do more to promote ... Most hospital patients cannot identify -- by name or role ... study of one urban hospital suggests. , "The majority of ... anybody in charge of their care," said study author Dr. ...
... asset to the global practice of radiologyBOSTON, Feb. ... ), a leader in radiology and medical image ... of Directors member Dr. Phillip Berman passed away ... lung cancer. Dr. Berman was 55 years old.(Logo: ...
Cached Medicine News:Health News:College Kids and Monkeys About Equal on Math 2Health News:ATS Medical Announces Fourth Quarter 2008 Earnings Release Date and Conference Call 2Health News:Invitation to Keith Olbermann 2Health News:Many Hospital Patients Can't ID Their Doctors 2Health News:Many Hospital Patients Can't ID Their Doctors 3Health News:AMICAS Mourns the Passing of Board Member Dr. Phillip Berman 2
... kits that quantitatively measure two important cardiac ... elevated serum or plasma homocysteine level is ... risk factor for cardiovascular disease. And numerous ... elevated levels of Lp(a) with increased risk ...
... Our test menu includes kits that quantitatively ... and lipoprotein (a). An elevated serum or ... a strong and independent risk factor for ... early 1970s have associated elevated levels of ...
... Professional Diagnostics is a leading provider of ... DFA test menu that includes kits for ... well as miscellaneous conjugates and components. Our ... wide assortment of substrates and kit sizes ...
... products for autoimmune testing feature single-well ANA ... as specific reflex tests including dsDNA, and ... (Ro), SS-B (La), Scl-70 and Jo-1. In ... full line of products for Cardiolipins (IgA, ...
Medicine Products: